Creative Planning’s Harvard Bioscience HBIO Stock Holding History

Creative Planning’s Portfolio HBIO Stock Details HBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-81	Closed	-$2K	–	2665
2017 Q2	$2K	Buy	+81	New	+$2K	﹤0.01%	4302
2016 Q1	–	Sell	-410	Closed	-$14K	–	4406
2015 Q4	$14K	Buy	+410	New	+$14K	﹤0.01%	3069
2015 Q1	–	Sell	-4	Closed	–	–	4295
2014 Q4	$0	Buy	+4	New	+$191	﹤0.01%	4231

Other funds holding HBIO

FLAM

First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

Heartland Advisors Milwaukee, Wisconsin $1.96B AUM 28.26% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

GPC

Glacier Peak Capital Bellevue, Washington $96.2M AUM 0.45% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

SBH

Segall Bryant & Hamill Chicago, Illinois $6.98B AUM 34.78% 1-Year Est. Return

Foundry Partners Minneapolis, Minnesota $1.89B AUM 9.84% 1-Year Est. Return

Creative Planning's HBIO Position: Q3 2017 in Review

Creative Planning sold out of Harvard Bioscience (HBIO) in Q3 2017, closing a stake of 81 shares — an estimated $2K sold.

Creative Planning first reported a position in HBIO in Q4 2014 and held it in 3 quarters. The position peaked at $14K in Q4 2015. 53 funds tracked by Wall St. Rank hold HBIO as of Q3 2017.

Creative Planning reported no remaining Harvard Bioscience position as of Q3 2017 after selling out during the quarter.
Creative Planning sold 81 Harvard Bioscience shares in Q3 2017, an estimated $2K.
Creative Planning first reported a position in Harvard Bioscience in Q4 2014 and held it in 3 quarters.
Creative Planning's Harvard Bioscience position peaked at $14K in Q4 2015.
53 funds tracked by Wall St. Rank held Harvard Bioscience as of Q3 2017.

Based on Creative Planning's 13F filing for Q3 2017, filed 17 Oct 2017.